Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
Want to see MLYS full AI Analyst Report?
MLYS Stock Chart & Stats
$30.58
-$0.99(-7.63%)
At close: 4:00 PM EST
$30.58
-$0.99(-7.63%)
Day’s Range― - ―
52-Week Range$12.59 - $47.65
Previous CloseN/A
Volume137.34K
Average Volume (3M)1.54M
Market Cap
$1.95B
Enterprise Value$1.98B
Total Cash (Recent Filing)$646.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding82,498,100
10 Day Avg. Volume2,288,255
30 Day Avg. Volume1,543,204
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)3.80
Price to Sales (P/S)0.00
P/FCF Ratio-17.24
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.39K
Enterprise Value/Ebitda-11.81
Forecast
1Y Price Target
$51.17Price Target Upside67.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory MilestoneNDA acceptance with a firm PDUFA date materially reduces regulatory binary risk and allows disciplined commercialization planning. Over the next 2–6 months this supports resource allocation, partner negotiations and launch sequencing, improving visibility into potential U.S. market entry timing.
Robust Clinical DatasetA broad Phase 3 package across multiple trials and populations (including high Black/African‑American representation and CKD signals) underpins clinical differentiation and payer conversations. Durable efficacy and tolerability bolster formulary access and long-term prescriber uptake if approved.
Cash Runway And Balance SheetA sizable cash position and improved equity base provide operational flexibility to fund regulatory activities, prelaunch build and potential milestone payments. Having runway into 2028 reduces near-term financing urgency and supports executing commercialization or partnering strategies.
Bears Say
Pre-revenue ProfileAbsence of product revenue means ongoing losses must be funded externally until commercial sales or licensing emerge. This structural cash reliance increases execution risk around launch, pricing, and market uptake and keeps returns on capital negative until revenue materializes.
Persistent Cash BurnMeaningful negative operating and free cash flow reflects continued high spend for trials and prelaunch activity. Even with some recent improvement, sustained burn pressure necessitates further financing or rapid commercialization to avoid dilution or covenant-driven constraints over the medium term.
Increased Leverage & DilutionConsolidating IP and repurchasing royalties improves future economics but materially raises near‑term cash commitments and added secured debt with covenants. Combined with an equity raise, capital structure changes heighten financial obligations and reduce flexibility if commercial performance lags expectations.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $12.59 and its highest was $47.65 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $1.95B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 72 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on May 06, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.472 by $0.002.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 82,498,100 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.472. Following the earnings report the stock price went down -2.556%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mineralys Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.17 (67.32% Upside)
$51.17 (67.32% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 514.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $8.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Bullish
Bullish news 79%
Bearish news 38%
Bearish news 38%
Technicals
SMA
Negative
20 days / 200 days
Momentum
51.66%
12-Months-Change
Fundamentals
Return on Equity
-27.92%
Trailing 12-Months
Asset Growth
83.94%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
MLYS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive progress on the clinical and regulatory front with NDA acceptance and a clear PDUFA date, supported by a broad dataset and active prelaunch preparations. Financially, the company retains a substantial cash balance with runway into 2028 and showed reduced R&D spend following completion of pivotal work. Offsetting risks include a sizeable increase in G&A/prelaunch costs, continued quarterly net losses, competitive timing and pricing pressure from AstraZeneca’s expected earlier launch, and unresolved partnering and labeling/pricing uncertainties. On balance, the company appears well positioned operationally and clinically, but near-term commercial and financial execution risks remain.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$51.17
▲(67.32% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
―
NewAmsterdam Pharma Company
―
Centessa Pharmaceuticals
―
Ownership Overview
27.04% Insiders
17.84% Mutual Funds
23.36% Other Institutional Investors
21.88% Public Companies and
Individual Investors